FEATURED

Q&A With Kristian Thidemann Andersen, MD

Cancer Therapy Advisor asked Dr Andersen about whether it is possible to improve outcomes among patients with multiple myeloma by identifying those at risk of infection among the transplant-eligible.

Fact Sheet: Calcium and Cancer

Evidence is mixed about the relationship between calcium intake and colorectal/prostate cancers.

Checkpoint Inhibition in Multiple Myeloma

Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is unlikely to work for patients with the disease?

CAR T Cell Therapy for Acute ...

Enthusiasm for the CAR T cell approach may redirect rather than augment other possibly safer, more effective, evolutionarily informed approaches to cancer therapy.

Fact Sheet: Aspartame and Cancer

Despite controversy, many studies have found no significant association between aspartame consumption and the incidence of different types of solid and hematologic malignancies.

Liquid Biopsies for CTCs

While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.

Fact Sheet: Vitamin A and Cancer

Vitamin A supplementation likely does not reduce chemotherapy efficacy and, for many patients, is unlikely to cause harm.

Axitinib for Metastatic Renal Cell Carcinoma

Axitinib is an efficacious drug among patients with metastatic RCC, though selecting the appropriate patients for treatment and the correct dose can be difficult.

Telotristat for Diarrhea in Carcinoid Syndrome

Telotristat represents a new treatment option that may decrease diarrhea incidence with a relatively safe side effect profile.

Racial Disparities in Prostate Cancer Outcomes

Increased insurance and clinical trial access, plus diversification of the medical workforce, may help to close treatment gaps.

Ask The Experts: Treating Sarcoma

Cancer Therapy Advisor interviewed 3 experts about how to best treat sarcoma.

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

In ER+, early-stage breast cancer

Individualizing treatment with extended adjuvant endocrine therapy

For the treatment of metastatic non-small

Biomarker testing for epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations is important when considering a first-line therapy

Looking for a Job?

Access our job board to view over 1,​200 job openings throughout the US.

Treatment Regimens

A full listing of cancer treatment and drug information is available to access.

In ER+, early-stage breast cancer

Experts discuss risk vs benefit of extended adjuvant endocrine therapy

Explore a combination therapy

Read about a triplet-based therapy for multiple myeloma patients who have received at least one prior treatment.

Latest Features

Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT

Q&A With Kristian Thidemann Andersen, MD, PhD: Infection in Multiple Myeloma After HDT-ASCT

Cancer Therapy Advisor asked Dr Andersen about whether it is possible to improve outcomes among patients with multiple myeloma by identifying those at risk of infection among the transplant-eligible.

Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

Checkpoint Inhibition in Multiple Myeloma After Pembrolizumab-related Clinical Trial Deaths

Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is unlikely to work for patients with the disease?

CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective

CAR T Cell Therapy for Acute Lymphoblastic Leukemia: An Evolutionary Perspective

Enthusiasm for the CAR T cell approach may redirect rather than augment other possibly safer, more effective, evolutionarily informed approaches to cancer therapy.

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.

In Focus: Axitinib for Metastatic Renal Cell Carcinoma

In Focus: Axitinib for Metastatic Renal Cell Carcinoma

Axitinib is an efficacious drug among patients with metastatic RCC, though selecting the appropriate patients for treatment and the correct dose can be difficult.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters